Skip to content

Press Release

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

✨ Onyx Summary Phathom Pharmaceuticals (Nasdaq: PHAT) announced its participation at the 2025 American College of Gastroenterology Annual Scientific Meeting, where it will highlight VOQUEZNA® (vonoprazan) as an approved treatment for gastroesophageal reflux disease (GERD) through a product theater presentation and exhibit booth engagement. The company aims to strengthen its leadership

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

✨ Onyx Summary Nuvation Bio (NYSE: NUVB) announced the enrollment of the first patient in Part 2 of its global G203 trial evaluating safusidenib, an oral IDH1 inhibitor, as maintenance therapy for high-grade IDH1-mutant astrocytoma following standard treatment. The study, now expanding into a Phase 3 registration trial with approximately 300

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

✨ Onyx Summary Geron Corporation (Nasdaq: GERN) granted inducement equity awards totaling approximately 3.08 million shares to four newly hired employees, including stock options and restricted stock units, under its 2018 Inducement Award Plan. The awards, approved by the Board’s Compensation Committee pursuant to Nasdaq Rule 5635(c)(4)

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

✨ Onyx Summary Perspective Therapeutics (NYSE American: CATX) reported updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-expressing neuroendocrine tumors, showing strong tolerability with no dose-limiting toxicities and encouraging anti-tumor activity, including confirmed responses in 44% of patients with uniform

Verily Launches a New Consumer Health App, Verily Me, at HLTH USA 2025

Verily Launches a New Consumer Health App, Verily Me, at HLTH USA 2025

✨ Onyx Summary Verily announced the launch of Verily Me, a new consumer health app showcased at HLTH USA 2025, designed to integrate clinical insights, personal health data, and AI assistance to help users manage their health and close care gaps. Built on Verily’s precision health platform and linked to

Seer to Report Third Quarter 2025 Financial Results on November 6, 2025

Seer to Report Third Quarter 2025 Financial Results on November 6, 2025

✨ Onyx Summary Seer, Inc. (Nasdaq: SEER) announced it will report third quarter 2025 financial results on November 6, 2025, followed by a webcasted conference call. The update comes as Seer continues to expand adoption of its Proteograph Product Suite, reinforcing its position as a leading provider of scalable, high-precision proteomic

Avidity Biosciences to Participate in Upcoming Investor Conference

Avidity Biosciences to Participate in Upcoming Investor Conference

✨ Onyx Summary Avidity Biosciences (Nasdaq: RNA) will participate in a panel discussion at the Chardan 9th Annual Genetic Medicines Conference on October 21, 2025, in New York. The engagement underscores Avidity’s leadership in RNA therapeutics as it advances its Antibody Oligonucleotide Conjugate (AOC™) platform across clinical programs in rare

Belite Bio to Participate in the 2025 Maxim Growth Summit

Belite Bio to Participate in the 2025 Maxim Growth Summit

✨ Onyx Summary Belite Bio (NASDAQ: BLTE) will participate in the Maxim Growth Summit on October 22, 2025, with executive management available for one-on-one meetings. The appearance highlights investor outreach as the company advances Tinlarebant through late-stage studies in STGD1 (DRAGON, DRAGON II) and GA in dry AMD (PHOENIX). SAN DIEGO,

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

✨ Onyx Summary Keros Therapeutics announced agreements to repurchase all shares held by ADAR1 Capital Management and Pontifax Venture Capital for approximately $181 million at $17.75 per share as part of its $375 million capital return program. Following the transactions, the company plans to launch a $194 million tender offer

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

✨ Onyx Summary enGene Holdings granted inducement equity awards totaling 93,200 stock options to three new employees, with an exercise price of $3.79 per share and a four-year vesting schedule. The grants, made under Nasdaq Listing Rule 5635(c)(4), align new hires’ incentives with shareholder interests as the

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

✨ Onyx Summary Belite Bio said China’s NMPA has accepted, with priority review, its NDA for Tinlarebant in Stargardt disease based on interim Phase 3 DRAGON results showing statistical significance on the primary endpoint. If approved, Tinlarebant would become the first therapy for Stargardt; Belite plans to report final topline

SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

✨ Onyx Summary SpyGlass Pharma reported 24-month interim results from its first-in-human trial of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), showing a 42% mean reduction in intraocular pressure and elimination of all topical medications in patients with open-angle glaucoma or ocular hypertension. The device demonstrated durable efficacy, safety, and improved